نتایج جستجو برای: ژن pik3ca

تعداد نتایج: 18195  

Journal: :Molecular cancer research : MCR 2015
Jaclyn F Hechtman Justyna Sadowska Jason T Huse Laetitia Borsu Rona Yaeger Jinru Shia Efsevia Vakiani Marc Ladanyi Maria E Arcila

UNLABELLED The PI3K/AKT/mTOR pathway is activated through multiple mechanisms in colorectal carcinoma. Here, the clinicopathologic and molecular features of AKT1 E17K-mutated colorectal carcinoma in comparison with PIK3CA-mutated colorectal carcinoma are described in detail. Interestingly, in comparison with PIK3CA mutants, AKT1 E17K was significantly associated with mucinous morphology and con...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2017
Nina Ilic Kıvanç Birsoy Andrew J Aguirre Nora Kory Michael E Pacold Shambhavi Singh Susan E Moody Joseph D DeAngelo Nicole A Spardy Elizaveta Freinkman Barbara A Weir Aviad Tsherniak Glenn S Cowley David E Root John M Asara Francisca Vazquez Hans R Widlund David M Sabatini William C Hahn

Oncogenic PIK3CA mutations are found in a significant fraction of human cancers, but therapeutic inhibition of PI3K has only shown limited success in clinical trials. To understand how mutant PIK3CA contributes to cancer cell proliferation, we used genome scale loss-of-function screening in a large number of genomically annotated cancer cell lines. As expected, we found that PIK3CA mutant cance...

2011
Filip Janku J. Jack Lee Apostolia M. Tsimberidou David S. Hong Aung Naing Gerald S. Falchook Siqing Fu Rajyalakshmi Luthra Ignacio Garrido-Laguna Razelle Kurzrock

BACKGROUND Oncogenic mutations of PIK3CA, RAS (KRAS, NRAS), and BRAF have been identified in various malignancies, and activate the PI3K/AKT/mTOR and RAS/RAF/MEK pathways, respectively. Both pathways are critical drivers of tumorigenesis. METHODS Tumor tissues from 504 patients with diverse cancers referred to the Clinical Center for Targeted Therapy at MD Anderson Cancer Center starting in O...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2009
Kevin Kalinsky Lindsay M Jacks Adriana Heguy Sujata Patil Marija Drobnjak Umeshkumar K Bhanot Cyrus V Hedvat Tiffany A Traina David Solit William Gerald Mary Ellen Moynahan

PURPOSE In breast cancer, somatic mutations in the PIK3CA gene are common. The prognostic implication of these activating mutations remains uncertain as moderately sized studies have yielded variable outcomes. Our aim was to determine the prognostic implications of PIK3CA mutations in breast cancer. EXPERIMENTAL DESIGN Archival formalin-fixed paraffin-embedded primary breast tumors, from 590 ...

2015
Ruza Arsenic Denise Treue Annika Lehmann Michael Hummel Manfred Dietel Carsten Denkert Jan Budczies

BACKGROUND Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha, PIK3CA, is one of the most frequently mutated genes in breast cancer, and the mutation status of PIK3CA has clinical relevance related to response to therapy. The aim of our study was to investigate the mutation status of PIK3CA gene and to evaluate the concordance between NGS and SGS for the most important hots...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2007
Mattia Barbareschi Fiamma Buttitta Lara Felicioni Sabrina Cotrupi Fabio Barassi Maela Del Grammastro Antonella Ferro Paolo Dalla Palma Enzo Galligioni Antonio Marchetti

PURPOSE In breast cancer, the PIK3CA gene is frequently mutated at "hotspots" in exons 9 and 20, corresponding to the helical and kinase domains, respectively. We decided to investigate the association of PIK3CA mutations with pathologic features and clinical outcome in a large series of patients with breast cancer. EXPERIMENTAL DESIGN Frozen samples from 163 consecutive patients were analyze...

Journal: :OncoTargets and therapy 2016
Qiong He Qi Xu Wei Wu Lei Chen Weijing Sun Jieer Ying

PURPOSE In metastatic or recurrent colorectal cancer (MRCRC), the concordance of Kirsten rat sarcoma viral oncogene homolog (KRAS) and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutation status between the primary tumors and metastases is still controversial. The purpose of this study was to evaluate the association between KRAS and PIK3CA mutational status ...

2012
Amaury G. Dumont Sarah N. Dumont Jonathan C. Trent

The phosphatidylinositol-3 kinase(PI3K) pathway regulates a number of cellular processes, including cell survival, cell growth, and cell cycle progression. Consequently, this pathway is commonly deregulated in cancer. In particular, mutations in the gene PIK3CA that encodes the p110α catalytic subunit of the PI3K enzymes result in cell proliferation and resistance to apoptosis in vitro and indu...

Journal: :PLoS ONE 2009
Shun Liang Nuo Yang Yue Pan Shan Deng Xiaojuan Lin Xiaojun Yang Dionyssios Katsaros Katherine F. Roby Thomas C. Hamilton Denise C. Connolly George Coukos Lin Zhang

BACKGROUND The Phosphatidylinositol 3'-kinase is a key regulator in various cancer-associated signal transduction pathways. Genetic alterations of its catalytic subunit alpha, PIK3CA, have been identified in ovarian cancer. Our in vivo data suggests that PIK3CA activation is one of the early genetic events in ovarian cancer. However, its role in malignant transformation of ovarian surface epith...

2012
C.B. Murat P.B.S. Braga M.A.H.Z. Fortes M.D. Bronstein M.L.C. Corrêa-Giannella R.R. Giorgi

The tumorigenesis of pituitary adenomas is poorly understood. Mutations of the PIK3CA proto-oncogene, which encodes the p110-α catalytic subunit of PI3K, have been reported in various types of human cancers regarding the role of the gene in cell proliferation and survival through activation of the PI3K/Akt signaling pathway. Only one Chinese study described somatic mutations and amplification o...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید